The pruritus of cholestasis is relieved by an opiate antagonist: is this pruritus a centrally mediated phenomenon?
Heathcote, J.
Hepatology 23(5): 1280-1282
1996
ISSN/ISBN: 0270-9139 PMID: 8621166 DOI: 10.1053/jhep.1996.v23.ajhep0231280
Accession: 047709770
PDF emailed within 0-6 h: $19.90
Related References
Jones, E.A.; Neuberger, J.; Bergasa, N.V. 2002: Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions Qjm: Monthly Journal of the Association of Physicians 95(8): 547-552Jones, E.A.; Neuberger, J.; Bergasa, N.V. 2002: Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions Qjm (Oxford 1994. Print) 95(8): 547-552
Jones, E.A.; Bergasa, N.V. 1990: The pruritus of cholestasis: from bile acids to opiate agonists Hepatology 11(5): 884-887
Bergasa, N.V.; Jones, E.A. 1991: Management of the pruritus of cholestasis: potential role of opiate antagonists American Journal of Gastroenterology 86(10): 1404-1412
Naoi, S.; Hayashi, H.; Inoue, T.; Tanikawa, K.; Igarashi, K.; Nagasaka, H.; Kage, M.; Takikawa, H.; Sugiyama, Y.; Inui, A.; Nagai, T.; Kusuhara, H. 2014: Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2 Journal of Pediatrics 164(5): 1219-1227.E3
Bergasa, N.V. 2018: The pruritus of cholestasis: from bile acids to opiate agonists: Relevant after all these years Medical Hypotheses 110: 86-89
Fjellner, B.; Hägermark, O. 1984: The influence of the opiate antagonist naloxone on experimental pruritus Acta Dermato-Venereologica 64(1): 73-75
Jones, E.A. 2002: Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions Journal of Hepatology 37(6): 863-865
Lonsdale-Eccles, A.A.; Carmichael, A.J. 2009: Opioid antagonist for pruritus of cholestasis unmasking bony metastases Acta Dermato-Venereologica 89(1): 90
Heyer, G.; Dotzer, M.; Diepgen, L.T.; Handwerker, O.H. 1997: Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis Pain 73(2): 239-243
Bigliardi, P.L.; Stammer, H.; Jost, G.; Rufli, T.; Büchner, S.; Bigliardi-Qi, M. 2007: Treatment of pruritus with topically applied opiate receptor antagonist Journal of the American Academy of Dermatology 56(6): 979-988
Ferreira-Marques, J. 1953: Concept and treatment of pruritus ani idiopathicus; vitamin a therapy of pruritus ani; pruritus ani as a physiopathological syndrome of the circumanal glands Archiv für Dermatologie und Syphilis 197(1): 85-90
Stander, S. 2006: Rationelle symptomatische Therapie bei chronischem Pruritus : Pruritus - Rational symptomatic therapy for chronic pruritus Hautarzt 57(5): 403-410
Böttcher, B.; Wildt, L. 2014: Treatment of refractory vulvovaginal pruritus with naltrexone, a specific opiate antagonist European Journal of Obstetrics Gynecology and Reproductive Biology 174: 115-116
Metze, D.; Reimann, S.; Luger, T.A. 1999: Effective treatment of pruritus with naltrexone, an orally active opiate antagonist Annals of the new York Academy of Sciences 885: 430-432
Bernstein, J.E. 2000: Opiate-mediated pruritus and citation etiquette Journal of the American Academy of Dermatology 43(2 Pt 1): 324-325
Neuberger, J.; Jones, E.A. 2001: Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy European Journal of Gastroenterology and Hepatology 13(11): 1393-1394
Kunzmann, S.; Kullak-Ublick, G.A.; Greiner, A.; Jeschke, R.; Hebestreit, H. 2005: Effective opiate-receptor antagonist therapy of cholestatic pruritus induced by an oral contraceptive Journal of Pediatric Gastroenterology and Nutrition 40(5): 596-599
Mettang, T.; Streit, M.; Weisshaar, E. 2006: Pruritus bei inneren Erkrankungen : Pruritus - Pruritus with systemic diseases Hautarzt 57(5): 395-402
Metze, D.; Reimann, S.; Beissert, S.; Luger, T. 1999: Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases Journal of the American Academy of Dermatology 41(4): 533-539